Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Frey

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
The New England Journal of Medicine|June 23, 2001
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofibanC P Cannon, W S Weintraub, L A Demopoulos, et al.
American Heart Journal|June 30, 2000
First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trialsR P Giugliano, C H McCabe, R F Sequeira, et al.
JAMA|December 26, 2001
Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trialD A Morrow, C P Cannon, N Rifai, et al.
Circulation|January 25, 2000
Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trialJ A de Lemos, E M Antman, C M Gibson, et al.
Journal of the American College of Cardiology|November 7, 1999
Determinants of coronary blood flow after thrombolytic administration. TIMI Study Group. Thrombolysis in Myocardial InfarctionC M Gibson, S Murphy, I B Menown, et al.
European Heart Journal|November 10, 2000
Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 InvestigatorsE M Antman, C M Gibson, J A de Lemos, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
The New England Journal of Medicine|June 23, 2001
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofibanC P Cannon, W S Weintraub, L A Demopoulos, et al.
American Heart Journal|June 30, 2000
First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trialsR P Giugliano, C H McCabe, R F Sequeira, et al.
JAMA|December 26, 2001
Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trialD A Morrow, C P Cannon, N Rifai, et al.
Circulation|January 25, 2000
Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trialJ A de Lemos, E M Antman, C M Gibson, et al.
Journal of the American College of Cardiology|November 7, 1999
Determinants of coronary blood flow after thrombolytic administration. TIMI Study Group. Thrombolysis in Myocardial InfarctionC M Gibson, S Murphy, I B Menown, et al.
European Heart Journal|November 10, 2000
Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 InvestigatorsE M Antman, C M Gibson, J A de Lemos, et al.
Pageof 4